Randomised controlled trial of Compensatory Cognitive Training and a Computerised Cognitive Remediation programme

Frances Dark 1, Ellie Newman 2, Victoria Gore-Jones 1*, Veronica De Monte 1, Marta I. Garrido 3,4 and Ivana Dzafic 3,4

Abstract

Background: Compensation and adaptation therapies have been developed to improve community functioning via improving neurocognitive abilities in people with schizophrenia. Various modes of delivering compensation and adaptation therapies have been found to be effective. The aim of this trial is to compare two different cognitive interventions, Compensatory Cognitive Training (CCT) and Computerised Interactive Remediation of Cognition–Training for Schizophrenia (CIRCuiTS). The trial also aims to identify if mismatch negativity (MMN) can predict an individual’s response to the compensation and adaptation programmes.

Methods: This study will use a randomised, controlled trial of two cognitive interventions to compare the impact of these programmes on measures of neurocognition and function. One hundred clinically stable patients aged between 18 and 65 years with a diagnosis of a schizophrenia spectrum disorder will be recruited. Participants will be randomised to either the CCT or the CIRCuiTS therapy groups. The outcome measures are neurocognition (BACS), subjective sense of cognitive impairment (SSTICS), social functioning (SFS), and MMN (measured by EEG) in people with schizophrenia spectrum disorders.

Discussion: This trial will determine whether different approaches to addressing the cognitive deficits found in schizophrenia spectrum disorders are of comparable benefit using the outcome measures chosen. This has implications for services where cost and lack of computer technology limit the implementation and dissemination of interventions to address cognitive impairment in routine practice. The trial will contribute to the emerging evidence of MMN as a predictor of response to cognitive interventions.

Trial registration: Australian New Zealand Clinical Trials Registry (ANZCTR) ACTRN12618000161224. Registered on 2 February 2018. Protocol version: 4.0, 18 June 2018.

Keywords: Cognitive remediation, Schizophrenia, Cognitive functioning, Neurocognition
Introduction

Background and rationale

Functional deficits (i.e. social skills, community functioning) are a core feature of schizophrenia. They represent key diagnostic criteria for the disorder that precede illness onset and are a strong predictor of outcome. These deficits do not respond to current psychopharmacology [1–3], thus underscoring the need to develop alternative interventions such as psychosocial treatments to address functional impairments.

Over the last 15 years, there has been renewed awareness of the impact of cognitive impairment in schizophrenia and the effect these deficits have on recovery and treatment outcomes [4, 5]. Compensation and adaptation therapies have been defined as “behavioural training-based intervention that aims to improve cognitive processes (attention, memory, executive functioning, social cognition or meta cognition with the goal of durability and generalisation)” [6]. A meta-analysis published in 2011 demonstrated that compensation and adaptation therapies had an overall effect size of 0.45 on global cognition with larger effect when combined with adjunctive rehabilitation (ES = 0.59) [6].

The research to date has not been able to refine who responds to cognitive compensation and adaptation therapies. There is interest in objective tests such as electroencephalography (EEG). EEG findings of attenuation in mismatch negativity (MMN) in auditory oddball tasks are one of the most robust and replicable neurophysiological markers of schizophrenia [7]. The MMN response occurs when a rare, unexpected sound is played in a repetitive sequence of sounds and is thought to reflect a brain response to an error in what is predicted. This sensory prediction error response has also been shown to relate to functional ability in people at risk for schizophrenia [8]. There are pilot studies indicating it may be able to predict and be an objective indicator of people who would benefit from psychosocial interventions [9–11]. Being able to have more precise information on who would respond to interventions, especially psychosocial interventions that require a weekly commitment over months, would benefit participants and not expose people to the potentially demoralising effect of attending a therapy that they were not able to benefit from [12].

Many cognitive remediation programmes are delivered via computer-based programmes often accessed online [6]. The cost of the infrastructure requirements of these programmes can pose a barrier to their implementation in some services. Pen and paper programmes to address cognitive deficits have been previously developed and evaluated [6]. This study is aimed at comparing a pen and paper cognitive adaption programme (CCT) [13–15] with a computer-based cognitive remediation programme, CIRCuiTS [16].

Objectives

This study will use a randomised controlled trial to test the equivalence of CCT compared with CIRCuiTS to address the cognitive deficits of schizophrenia spectrum disorders. The primary objective is to examine the equivalence of CCT in improving neurocognitive deficits in people with schizophrenia spectrum disorders compared with CIRCuiTS. The secondary objective examines if CCT and/or CIRCuiTS are associated with objective and subjective improvement in community and cognitive functioning. In addition, we aim to determine whether MMN at baseline can be used to predict on an individual level, who might benefit from either treatment.

Trial design

The design is a single-blind, randomised controlled trial to examine the equivalence of CCT and CIRCuiTS. The trial also aims to examine if MMN at baseline can predict response to the compensation and adaptation therapies and if MMN improves from baseline to post-treatment.

The study will include 100 clinically stable patients with a schizophrenia spectrum disorder. Participants will be randomised in a 1:1 ratio to join either the CCT group or the CIRCuiTS group. Participants will all be active cases in Metro South Addiction and Mental Health Services (community based). Participants in the study will continue to receive standard clinical care (i.e. there are no restrictions on medication or psychosocial interventions, apart from participants receiving therapies addressing neurocognition). These two interventions will be delivered by trained mental health staff once (CCT 2-h session) or twice (CIRCuiTS 1-h sessions) per week for 12 weeks. Groups will be based on a maximum of 6 participants per facilitator. Individual clinical assessments will be at baseline, at post-treatment, and at 3-month follow-up. Randomisation will be carried out using a computer-generated randomisation table.

Method: participants, interventions, and outcomes

Study setting

The study will be conducted in the Community Mental Health Centres within Metro South Addiction and Mental Health Services, Queensland, Australia.

Eligibility criteria

The specified inclusion criteria are as follows: (1) aged between 18 and 65 years (inclusive), (2) fulfilling the clinical diagnosis of DSM-V criteria for schizophrenia spectrum disorder, (3) absence of uncorrected sensory impairments, (4) English literacy skills greater than grade 4 as per years of education, and (5) agreement to participate, with capacity to consent and able to follow the study instructions and procedures.
The specific exclusion criteria are as follows: (1) presence of substance dependence (with the exception of tobacco), (2) intellectual handicap (estimated using the Test of Premorbid Functioning (TOPF)), (3) people who are unable to understand or communicate in English or with English literacy skills less than grade 4 as per years of education, and (4) comorbid physical illnesses that would impair the participants’ ability to complete the trial.

Interventions
All participants will continue in treatment as usual but will be asked not to be involved in other research or any therapy intervention aimed at improving their cognition until the study is completed. Participant withdrawal by the investigator will be determined by deterioration of mental state such that the participant is admitted to hospital or their ability to provide ongoing informed consent is compromised.

The investigator is responsible for the detection and documentation of events meeting the criteria and definition of an adverse event or serious adverse event as provided in this protocol. All adverse events will be recorded between the time of consent, intervention, and follow-up visits. Each participant will be monitored regularly by the investigator and study personnel for adverse events occurring throughout the study. The research team will enquire about adverse events by asking the following non-leading questions. At the first scheduled visit (baseline), participants will be asked:

“How are you feeling? Does your current treatment cause you regular side effects? Do you have any general health conditions that cause you problems on a regular basis (e.g. that we might expect to occur over the duration of this study)?”

At subsequent scheduled visits, participants will be asked:

“How are you feeling? Does your current treatment cause you regular side effects? Do you have any general health conditions that cause you problems on a regular basis (e.g. that we might expect to occur over the duration of this study)?”

Compensation and adaptation therapies will be delivered by two experienced CCT and CIRCuiTS therapists (FD and VDM) and co-facilitators. FD will facilitate the CCT groups and VDM will facilitate the CIRCuiTS groups. Supervision will be provided by the experienced therapists (FD and VDM). The therapy groups will be run at public mental health services community sites.

Compensatory Cognitive Training
CCT is a 2-h ×12 session manualised cognitive compensatory training programme that focusses on the use of strategies to improve real-world cognitive functioning. The manual covers exercises in prospective memory, attention, memory, and executive functioning. There are some drill and practice of tasks, but the emphasis is on strategy use and incorporation into everyday activities. CCT is delivered through paper and pen tasks.

CIRCuiTS
CIRCuiTS (Computerised Interactive Remediation of Cognition–Training for Schizophrenia) is a modular package including tasks of a wide range of cognitive functions (particularly executive function and memory), intended to allow therapy programmes to be flexibly designed to incorporate only relevant tasks. Prior to attempting a task, the participant needs to register how long they believe the task will take, how difficult the task is expected to be, and the strategy they intend to use. They receive computer feedback on these dimensions and re-rate how useful the strategies were with the goal of developing metacognitive knowledge and awareness. CIRCuiTS is run for 1 h twice a week and is delivered through a computer. The CIRCuiTS programme used consists of 40 stages. The tasks are progressively more difficult as the participant works through the programme. Twenty sessions are considered an adequate treatment exposure.

Outcomes
A battery of validated clinical measures will be conducted at baseline, at post-treatment, and at 3-month follow-up. Raters who are blind to the randomisation of condition (registered psychologists) will complete the measures. The assessors instruct the participant not to reveal their group allocation.

The following measures will be used:

1. Brief Assessment of Cognition in Schizophrenia (BACS) [17] is an instrument that assesses the aspects of cognition found to be most impaired and most strongly correlated with outcome in patients with schizophrenia. This is the primary outcome measure.
2. Test of Premorbid Functioning (TOPF) [18] is a test of premorbid intelligence as estimated from reading ability.
3. Subjective Scale to Investigate Cognition in Schizophrenia (SSTICS) [19]. This measures the perception of cognitive abilities when completing everyday tasks.
4. Social Functioning Scale (SFS) [20] assesses areas of functioning that are crucial to the community maintenance of individuals with schizophrenia.
5. Brief Psychiatric Rating Scale (BPRS) [21] is a widely used scale for measuring symptom severity of patients with schizophrenia.
6. Electroencephalography (EEG). Participants will listen to a duration auditory oddball paradigm while their brain responses are measured with EEG. An auditory oddball paradigm consists of presentations of sequences of predictable sound stimuli (standard sounds) that are infrequently interrupted by unpredictable sound stimuli (deviant sounds). Sounds will be delivered via headphones and will vary in duration. All tones will be presented in a sound range that is comfortable for the participants. In the “volatility” auditory oddball task, the participants will be asked to pay attention to the sounds in order to judge the proportion of different sound types and rate their confidence on this judgement. This will allow us to assess the ability of participants to learn the statistical relationships of sound types, as well as the confidence on their own judgement. Prior to the experiment, the participants will be familiarised with the different sound types and trained with two short practice tasks. Participants will make responses using a computer keyboard and a mouse. The duration of the practice task will be 2 min, and the duration of the volatility auditory oddball task will be approximately 18 min, with a total duration of testing of approximately 20 min per participant, including breaks.

The TOPF, SSTICS, BPRS, and EEG are secondary outcome measures.

Participant timeline
The study will include clinically stable patients, living in the community with a diagnosis of a schizophrenia spectrum disorder receiving community-based clinical care in Metro South Addiction and Mental Health Services. These two interventions will be delivered by trained and experienced mental health staff once or twice per week for 12 weeks. Groups will be based on two to six participants per group. Individual clinical assessments will be at baseline, post-intervention, and 3-month follow-up (see Fig. 1).

Sample size
In this equivalence study, we will focus on the primary outcome of cognition. We based our power analysis specifically on the BACS. We estimate a dropout rate of 15–20% (from treatment to 3-month follow-up) resulting in a final sample size of approximately 80 participants who will complete the study. This estimate is based on the dropout rates for studies with participants with serious mental illness as well as our experience with group randomised controlled trial research. Due to practicalities of group size and opportunities for running groups over the study timeframe, the maximum number of participants was set at one hundred.

Recruitment
Participants will be recruited through the public mental health community clinics. Participants will continue to receive standard clinical care for the duration of the study. Medication prescribed at baseline will be collected and any changes noted. Participants will not be compensated for their time spent in treatment or assessment sessions.

Methods: assignment of interventions
Allocation and blinding
A minimum of twelve participants will be recruited for each round of the study. Participants will be recruited and randomly allocated in block sizes of four using randomisation procedure Statistical Analysis System (SAS) 9.4 by a member of the research team not involved in the delivery of the intervention or outcome assessment. As participants may drop out of therapy, the group numbers may fall to no lower than two participants. The therapeutic group size is two to six participants. Information about the treatment allocation will be emailed to the therapists who will contact participants about their therapy.

A battery of validated clinical measures will be conducted by trained research assistants, who are blind to group membership, at baseline, post-intervention, and 3-month follow-up. The research staff who undertake the outcome assessments will be blind to group allocation and will advise participants not to reveal their treatment. If a patient reveals this information, this will be noted for post hoc analyses of the data.

Methods: data collection, management, and analysis
Data collection and statistical methods
The primary efficacy analysis will assess average treatment group differences for the primary outcome measure BACS, over the entire study period (baseline, post-intervention, follow-up), and will use a likelihood based mixed-effects model, repeated measures (MMRM) approach. The MMRM model includes the fixed, categorical effects of treatment (CCT or CIRCuiTS), visit (baseline, 12 and 24 weeks), and treatment-by-visit interaction, as well as the continuous, fixed covariates of baseline score and baseline score-by-visit interaction. The MMRM includes all available data at each time point and is the preferred method of analysing clinical trial data in psychiatry as compared to more traditional repeated measures analysis of variance (ANOVA) and analysis of covariance (ANCOVA) models. Planned comparisons will be done with the MMRM models to determine between-group differences in change.
of symptoms measures from baseline to weeks 12 and 24. Results from the analysis of dichotomous data will be presented as proportions, with 95% confidence interval, and Fisher's exact p value where appropriate. Non-parametric statistics will be used when assumptions for parametric methods are violated. Effect sizes will be calculated using Cohen's guidelines. All tests of treatment effects will be conducted using a two-sided alpha level of 0.05 and 95% confidence intervals.

**EEG data collection and preprocessing**
The EEG data will be collected with the AntNeuro EegoSport system, 64-electrode head cap at a sampling rate of 1024 Hz. The data will be downsampled to 200 Hz, high-pass filtered at 0.5 Hz, and low-pass filtered at 40 Hz using the Butterworth filter. The data will be epoched offline with a peri-stimulus window of −100 to 400 ms, and baseline correction will be applied between −100 and 0 ms. Next, artefact rejection will be performed by thresholding all channels at 100 uV and rejecting channels based on a 0.2-V threshold. We will then reference all the electrodes to the average reference. Finally, averaging will be conducted across all the trials. We will analyse event-related potentials from the onset of standard and oddball sounds, separately for stable and volatile conditions.

---

**STUDY PERIOD**

| Screen | Baseline | Week | Completion |
|--------|----------|------|-----------|
|        |          | 1    | 2         | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 12 | 13 | 24 |
| **WEEK** |          |      |           |   |   |   |   |   |   |   |   |   |   |   |
| **ENROLMENT:** |          |      |           |   |   |   |   |   |   |   |   |   |   |   |
| Eligibility screen | X |      |           |   |   |   |   |   |   |   |   |   |   |   |
| Informed consent | X |      |           |   |   |   |   |   |   |   |   |   |   |   |
| Inclusion/exclusion criteria | X |      |           |   |   |   |   |   |   |   |   |   |   |   |
| Allocation | X |      |           |   |   |   |   |   |   |   |   |   |   |   |
| **INTERVENTIONS:** |          |      |           |   |   |   |   |   |   |   |   |   |   |   |
| CCT |       |      |           |   |   |   |   |   |   |   |   |   |   |   |
| CIRCuits |   |      |           |   |   |   |   |   |   |   |   |   |   |   |
| **ASSESSMENTS:** |          |      |           |   |   |   |   |   |   |   |   |   |   |   |
| BACS | X |      |           | X | X |   |   |   |   |   |   |   |   |   |
| TOPF | X |      |           | X | X |   |   |   |   |   |   |   |   |   |
| SSTICS | X |      |           | X | X |   |   |   |   |   |   |   |   |   |
| SFS | X |      |           | X | X |   |   |   |   |   |   |   |   |   |
| BPRS | X |      |           | X | X |   |   |   |   |   |   |   |   |   |
| EEG oddball task | X |      |           |   |   |   |   |   |   |   |   |   |   |   |

*Fig. 1* Schedule of enrolment, intervention, and assessment
Cognitive intervention-related changes in brain and behaviour: single-channel and behavioural analyses

To investigate if MMN improves after the compensation and adaptation therapy programmes, we will conduct a repeated measures $2 \times 2 \times 3$ ANOVA design on mean ERP values, with MMN volatility (stable and volatile), treatment (CCT or CIRCuiTS), and visit (baseline, 12 and 24 weeks) as factors. Responders will be participants who make a clinically significant positive change based on the measures of cognition collected using Jacobson and Truax’s Reliable Change Index [22]. Mean ERP values will be obtained by averaging across the preselected time window of interest for MMN latency: 100–250 ms, over a frontocentral channel (Fz) [23]. In addition, we will investigate the behaviour, “regularity learning”, which is found to underlie the MMN response. We will conduct a separate repeated measures $2 \times 2 \times 3$ ANOVA design with the following factors: regularity learning (stable and volatile), treatment (CCT or CIRCuiTS), and visit (baseline, 12 and 24 weeks). This behavioural analysis will be conducted to examine if the compensation and adaptation therapy programmes improve regularity learning ability. Significant interactions will be further analysed using paired $t$ tests.

Predicting cognitive intervention response with machine learning: spatiotemporal maps and feature definition

To identify if EEG measures can be used to predict response to the compensation and adaptation therapies, we will use machine learning techniques to classify individual patients that benefit from the compensation and adaptation therapies (responders) from patients who do not improve after the compensation and adaptation therapies (non-responders). Machine learning will be implemented using the Pattern Recognition for Neuro-imaging Toolbox (PRoNTo) [23] with features from the whole-brain spatiotemporal analysis. First, we will create three-dimensional spatiotemporal images from averaged ERP data. A three-dimensional matrix $(32 \times 32 \times 81)$ corresponding to the scalp electrode space and time points will be constructed, per participant for the different conditions. The images will be smoothed at full width half maximum of 12 mm $\times$ 12 mm $\times$ 20 ms. Before conducting the machine learning, we will perform the standard spatiotemporal mass-univariate general linear model analysis. A full factorial analysis will be performed to examine the spatiotemporal changes after the therapy programmes, with the following factors: volatility (stable and volatile), treatment (CCT or CIRCuiTS), and visit (baseline, 12 and 24 weeks). All statistical maps will be thresholded at $p < 0.05$ family-wise error (FWE) corrected for multiple comparisons.

Next, we will conduct the machine learning analysis, and the three-dimensional spatiotemporal images will be fed as features into the classifier. To classify the compensation and adaptation therapy responders and non-responders, class labels will be assigned to each participant. In PRoNTo, we will apply the support vector machine (SVM) and Gaussian process algorithms [24], which has shown to be effective in classifying schizophrenia patients using neuro-imaging features [12]. The SVM training phase involves assigning weights to features and finding the hyperplane that maximises the margin between the groups of participants; the sign of the total feature weights multiplied by the test sample will determine the classification of participants. A $k$-fold cross-validation scheme will be conducted, dividing the group of participants into $k$ subgroups, and iteratively assigning subgroups for training or testing until all subgroups have been through the testing. Mean-centering will be performed on all models and normalisation will be applied. In order to attain statistical measures, permutation tests will be performed (1000 repetitions) for each model and cross-validation scheme. To correct for multiple comparisons, we will apply false discovery rate correction of $q = 0.05$. Model sensitivity and specificity will be determined using the receiver operating characteristic curve, which will show the true positive rate (sensitivity) as a function of false positive rate ($1 – specificity$). The area under the curve will determine how well we are able to differentiate between compensation and adaptation therapy responders and non-responders using the best classifier from the EEG data.

Finally, we will conduct regression modelling to examine model performance by comparing true compensation and adaptation therapies’ response with that response predicted by the model. Spatiotemporal images for each subject will be mapped to their BACS scores, and machine learning regression algorithm—Kernel Ridge Regression [25, 26]—will be trained to predict these scores. To determine the accuracy of predicted response to compensation and adaptation therapies, we will calculate mean-squared error, Pearson’s correlation, and coefficient of determination statistics. Again $k$-fold cross-validation will be applied, permutations will be conducted to attain statistical measures, and multiple comparisons will be Bonferroni corrected.

Data management

Researchers from Metro South Addiction and Mental Health Services will be responsible for data entry and analyses. Researchers from the Queensland Brain Institute will have access to the deidentified database to enter EEG data and perform analyses. Participants will be allocated a number to allow for their data from each time point to be linked for analyses.

A screening log will be utilised to track potential participants and record the number of individuals approached, consented, meeting inclusion/exclusion criteria, withdrawals,
and completion (in keeping with standard CONSORT diagram requirements). Hard copies of the questionnaires, clinical assessments, and measures will be sent to the clinical co-ordinator and retained in a secure room, in a locked filling cabinet. The trial coordinator will be responsible for entering data into the password-protected database. The researchers will conduct the data analyses.

Data monitoring
The trial management group (TMG) consists of the principal investigator (FD), the trial coordinator (VGI), and associate investigator (VDM) who are unblinded to condition. Adverse events are reviewed by the TMG and reported to the ethics committee. The process of recruitment and data management are overseen by this group. This trial may be subject to random auditing by the ethics committee.

Protocol amendments
Any amendments to the protocol will be submitted to the appointed HREC by the Chief Investigator for approval. Any approved amendments by the appointed HREC will be forwarded by the Chief Investigator for submission to the appropriate Research Governance Offices. If a protocol amendment requires changes to the informed consent form, the revised form will be approved by the reviewing ethics committees and site governance officers.

Dissemination policy
Results will be disseminated in peer review publications and published international journals. Only deidentified data will be reported. Results will be provided to participants on their request.

Discussion
Compensation and adaptation therapies have been demonstrated to improve neurocognitive functioning in people with schizophrenia spectrum disorders. The current study aims to evaluate the equivalence of two different compensation and adaptation therapies (CIRCuiTS and CCT) within a community mental health service. This study also aims to identify if mismatch negativity can predict an individual’s response to compensation and adaptation therapies. This knowledge will allow clinicians to identify individuals who are more likely to receive benefit from a compensation and adaptation therapy programme.

This RCT has several strengths. To date, no other study has incorporated neurophysiological measures of mismatch negativity to identify participants that may be more likely to benefit from compensation and adaptation therapies. This is a novel approach and may assist with identifying future participants of compensation and adaptation therapy programmes. Participants will be randomly assigned to each group, and the raters remain blind to condition to avoid bias. A variety of outcome measures will be used to assess functioning across neurocognitive, social, and neurophysiological domains.

No formal assessment of inter-rater reliability will be conducted. Groups will be matched for total exposure to therapy (2 h per week over 12 weeks). Participants in the CIRCuiTS group may not have completed all 40 phases prior to the post-intervention assessments. Clinician effects may influence the results as one therapist will deliver CCT and one will deliver CIRCuiTS.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s13063-020-04743-y.

Additional file 1.

Abbreviations
ANCOVA: Analysis of covariance; ANOVA: Analysis of variance; ANZCTR: Australian New Zealand Clinical Trials Registry; BACS: Brief Assessment of Cognition in Schizophrenia; BPRS: Brief Psychiatric Rating Scale; CIRCuiTS: Computerised Interactive Remediation of Cognition–Training for Schizophrenia; CCT: Compensatory Cognitive Training; CONSORT: Consolidated Standards of Reporting Trials; DSM-V: Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition; EEG: Electroencephalography; FWE: Family-wise error; HREC: Human research ethics committee; IQ: Intelligence quotient; MMN: Mismatch negativity; MMRM: Mixed-effects model repeated measures; NDCT: National Database for Clinical Trials Related to Mental Illness; ProNTo: Pattern Recognition for Neuroimaging Toolbox; RCT: Randomised controlled trial; SAS: Statistical Analysis System; SFS: Social Functioning Scale; SSTICS: Subjective Scale to Investigate Cognition in Schizophrenia; SVM: Support vector machine; TMG: Trial management group; TOPF: Test of Premorbid Functioning

Acknowledgements
The researchers acknowledge Professor Dame Til Wykes, Dr. Matteo Cella, and Dr. Clare Reeder for their support with CIRCuiTS and Professor Elizabeth Twamley who developed the CCT programme. Finally, we would like to thank all the research assistants, participants, and others involved in this study.

Trial status
The trial commenced in 2017 and recruitment will continue until late 2020. Protocol version 4.0, 18 June 2018.

Authors’ contributions
FD, EN, VDM, VGJ, MG, and ID contributed to the design of the study. FD and VGI drafted the protocol. FD and VD will run the compensation and adaptation therapy programmes, VGJ, VDM, and several psychologists and post-graduate psychology students will conduct the cognitive assessments, and ID will conduct the EEGs. MG and ID designed the EEG task and planned analyses. All authors have participated in the review and revision of the protocol manuscript and have approved the final manuscript to be published. No professional writers will be used. The sponsor (Metro South Addiction and Mental Health Services, Woolloongabba, Phone: 0731569800) was not involved in the design and conduct of the study; the management, analysis, or interpretation of data; or in the preparation, review, or approval of the manuscript for publication.

Funding
This trial was conducted with no external funding, and instead, in-kind funding was provided by Metro South Addiction and Mental Health Services.
Availability of data and materials
On completion of this study, the dataset will be made available from the corresponding author on reasonable request.

Ethics approval and consent to participate
This study was approved by the Metro South Human Research Ethics Committee (AU/1/1335223) and the University of Queensland Human Research Ethics Committee (Clearance Number: 201800062). All participation will be based on voluntary informed consent.

Consent for publication
Not applicable.

Competing interests
FD has received honorariums from Janssen and Lundbeck for the delivery of lectures at clinician educational events.

Author details
1 Metro South Addiction and Mental Health Services, 228 Logan Road, Woolloongabba, Queensland, Australia. 2 St Kilda Road Clinic, Community Adult Mental Health, Alfred Psychiatry, Melbourne, Australia. 3 Queensland Brain Institute, Centre for Advanced Imaging, Centre of Excellence for Integrative Brain Function, The University of Queensland, Brisbane, Queensland, Australia. 4 Melbourne School of Psychological Sciences, The University of Melbourne, Melbourne, Australia.

Received: 7 July 2019 Accepted: 16 September 2019
Published online: 29 September 2020

References
1. Bellack AS, Schooler NR, Marder SR, Kane JM, Brown CH, Yang Y. Do clozapine and risperidone affect social competence and problem solving? Am J Psychiatr. 2004;161:364–7.
2. Hogarty GE, Flesher S, Ulrich R, Carter M, Greenwald D, Pogue-Geile M, Kechavan M, Cooley S, DiBarry AL, Garrett N, Parepally H, Zoretich R. Cognitive enhancement therapy for schizophrenia: effects of a 2-year randomized trial on cognition and behavior. Arch Gen Psychiatr. 2004;61:866–76.
3. Sergi MJ, Rassovsky Y, Nuechterlein KH, Green MF. Social perception as a mediator of the influence of early visual processing on functional status in schizophrenia. Am J Psychiatr. 2006;163:48–54.
4. Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the ‘right stuff’? Schizophr Bull. 2000;26:119–36.
5. McGurk SR, Mueser KT, DeFosa TJ, Wolfe R. Work, recovery, and comorbidity in schizophrenia: a randomized controlled trial of cognitive remediation. Schizophr Bull. 2009;35:319–35.
6. Wykes T, Huddy V, Cellard C, McGurk R, Czobor P. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am J Psychiatr. 2011;168:472–85.
7. Catts SV, Shelley AM, Ward PB, Liebert B, McConaghy N, Andrews S, Michie PT. Brain potential evidence for an auditory sensory memory deficit in schizophrenia. J Psychiatr. 2004;161:364–7.
8. Light GA, Braff DL. Mismatch negativity deficits are associated with poor functioning in schizophrenia patients. Arch Gen Psychiatr. 2005;62:127–36.
9. Light GA, Swerdlov NR. Future clinical uses of neurophysiological biomarkers to predict and monitor treatment response for schizophrenia. Ann N Y Acad Sci. 2011;1244:105–19.
10. Hochberger WC, Joshi YB, Thomas ML, Zhang W, Bismark AW, Treichler EBH, Tarasenko M, Nungaray J, Sprock J, Cardoso L, Swerdlov N. Neurophysiological measures of target engagement predict response to behavorial cognitive training in treatment refractory schizophrenia. Neuropsychopharmacology. 2019;44:606–12.
11. Perez VB, Tarasenko M, Miyakoshi M, Pianka ST, Makeig SD, Braff DL, Swerdlov NR, Light GA. Mismatch negativity is a sensitive and predictive biomarker of perceptual learning during auditory cognitive training in schizophrenia. Neuropsychopharmacology. 2017;42:2206–13.
12. Taylor JA, Matthews N, Michie PT, Rosa MJ, Garrido M. Auditory prediction errors as individual biomarkers of schizophrenia. NeuroImage Clin. 2017;15:264–73.
13. Twamley EW, Vella L, Burton CZ, Heaton RK, Jeste DV. Compensatory Cognitive Training for psychosis effects in a randomised controlled trial. J Clin Psychiatr. 2012;73:1212–9.
14. Mendella PD, Burton CZ, Tass CA, Roy P, St Louis, L, Twamley EW. Compensatory Cognitive Training for people with first-episode schizophrenia: results from a pilot randomised controlled trial. Schizophr Res. 2015;162:108–11.
15. McGurk SR. Compensatory Cognitive Training for people with severe mental illnesses in supported employment: a randomised controlled trial. Schizophr Res. 2019;203:41–8.
16. Reeder C, Pile V, Crawford P, Cella M, Rose D, Wykes T, Watson A, Huddy V, Gallard F. The feasibility and acceptability to service users of CIROCUTs, a computerized cognitive remediation therapy programme for schizophrenia. Behav Cogn Psychother. 2016;44:288–305.
17. Keefe RSE, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour LR. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res. 2004;68:283–97.
18. Pearson Assessment. Advanced clinical solutions for the WAS-IV and WMS-IV: clinical and interpretive manual. San Antonio, Texas: NCS Pearson; 2009.
19. Stip E, Caron J, Renaud S, Pampoulou T, Lecomte Y. Exploring cognitive complaints in schizophrenia: the subjective scale to investigate cognition in schizophrenia. Compr Psychiatr. 2003;44:331–40.
20. Birchwood M, Smith J, Cochrane R, Wotton S, Copestake S. The Social Functioning Scale. The development and validation of a new scale of social adjustment for use in family intervention programmes with schizophrenic patients. Br J Psychiatr. 1990;157:853–9.
21. Lukoff D, Nuechterlein KH, Ventura J. Manual for expanded Brief Psychiatric Rating Scale. Schizophr Bull. 1986;12:594–602.
22. Jacobson NS, Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol. 1991;59:12–9.
23. Todd J, Michie PT, Schall U, Karayannis F, Yabe H, Naatanen R. Deviant matters: duration, frequency, and intensity deviants reveal different patterns of mismatch negativity reduction in early and late schizophrenia. Biol Psychiatr. 2008;63:58–64.
24. Schrouff J, Rosa MJ, Rondina JM, Marquand AF, Chu C, Ashburner J, Phillips C, Richard J, Mourão-Miranda J. PROTo: pattern recognition for neuroimaging toolbox. Neuroinformatics. 2013;11:319–37.
25. Cortes C, Vapnik V. Support-vector networks. Mach Learn. 1995;20:273–97.
26. Shawe-Taylor J, Cristianini N. Kernel methods for pattern analysis. Cambridge: Cambridge University Press; 2004.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.